Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8088094 | 1.00 | MAPT (0.55) | MAPTALDH1A1HTTTDP1ENPP2 | |
| SCHEMBL8079721 | 0.86 | MAPT (0.52) | MAPTALDH1A1HTR7KCNH2LMNA | |
| SCHEMBL13656461 | 0.86 | MAPT (0.52) | MAPTALDH1A1HTR7KCNH2LMNA | |
| SCHEMBL15445827 | 0.82 | MAPT (0.66) | MAPTALDH1A1HTTTDP1ENPP2 | |
| SCHEMBL8014422 | 0.74 | MAPT (0.71) | MAPTHTR7KCNH2LMNASMN1; SMN2 | |
| SCHEMBL18587973 | 0.73 | PTGS2 (0.44) | MAPTALDH1A1LMNAKMT2AACHE | |
| SCHEMBL15347670 | 0.68 | POLB (0.73) | MAPTALDH1A1TDP1LMNASMN1; SMN2 | |
| SCHEMBL5741339 | 0.68 | SIRT6 (0.62) | MAPTALDH1A1HTTTDP1LMNA | |
| SCHEMBL3637451 | 0.67 | KCNH2 (0.63) | MAPTALDH1A1HTTTDP1HTR7 | |
| SCHEMBL4249336 | 0.67 | KCNH2 (0.63) | MAPTALDH1A1HTTTDP1HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079852-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140031363-A1 | NMDA Receptor Antagonists for Neuroprotection | LIOTTA DENNIS C (US) | 2014-01-30 | — | — | US | disclosed |
| US-8420680-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2013-04-16 | — | — | US | disclosed |
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | EMORY UNIVERSITY | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | GRIN1, GRIN2C, GRIK1 | MAPT 2477/4885ALDH1A1 2664/4885HTT 1416/4885 |
| US-20140031363-A1 | NMDA Receptor Antagonists for Neuroprotection | GRIN1, GRIN2C, GRIK1 | MAPT 2536/4885ALDH1A1 2668/4885HTT 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.